cpi-1205
Generic: Lirametostat·Code: CPI-1205
cpi-1205: developed by 1 company · 1 clinical trial tracked.
cpi-1205 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect cpi-1205 to CNST; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could cpi-1205 → CNST affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| CONSTELLATION PHARMACEUTICALS INC (CNST) Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Efficacy: Best Objective Response Rate Percent by Treatment Group
InterventionalRandomizedopen175 enrolledStarted 2017-11Completion 2021-0241 sites · United StatesConstellation Pharmaceuticals
Frequently asked questions
Who is developing cpi-1205?
cpi-1205 is being developed by CONSTELLATION PHARMACEUTICALS INC.
How many clinical trials involve cpi-1205?
BioSniper tracks 1 clinical trial involving cpi-1205.